PRAMEF12

Across TCGA pan-cancer cohorts, PRAMEF12 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PRAMEF12 data layer compared with 17 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher PRAMEF12 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PRAMEF12 expression acts as an unfavorable survival marker.

KIRP, LUSC, and BLCA are the cancer types where PRAMEF12 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	OS	Median	II,III,IV	0.141	0.772	<.001	24	view →
LUSC	OS	Median	III,IV	0.126	0.664	.008	12	view →
BLCA	OS	Median	All	0.123	0.450	.010	11	view →
LUAD	OS	Median	All	0.312	0.702	.002	6	view →
SKCM	OS	Median	IV	0.415	0.861	.014	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PRAMEF12–KIRP (OS)

Open the KIRP breakdown →